Project Grant R01HL173431
Award Date 9/3/25
Completion Date 6/30/29
Dollars Obligated $713K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The primary objectives are to: 1) fully characterize at the atomic level three specific functional domains of the cardiac thin filament linked to the...
- This Project Grant award of $777,258 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to advance the understanding of heart failure in hypertrophic cardiomyopathy (HCM) and evaluate the impact of the cardiac myosin inhibitor mavacamten compared to surgical myectomy. The research, to be conducted by Beth Israel Deaconess Medical Center, Inc. from February 2025 through January 2030, will utilize cardiac magnetic resonance imaging...
- This $713,511 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the impact of myosin-binding protein C (MyBP-C) on myosin mobility and proteostasis in the context of hypertrophic cardiomyopathy (HCM). The University of Vermont & State Agricultural College, the awardee, will utilize innovative techniques to investigate how reduced MyBP-C levels, a common cause of HCM, may disrupt normal heart...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...
- The Project Grant award titled "STRUCTURE, FUNCTION AND DRUG TREATMENT OF THE NATIVE CARDIAC SARCOMERE IN HYPERTROPHIC CARDIOMYOPATHY" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $149,804. The award aims to utilize advanced cryo-electron tomography (cryo-ET) imaging techniques to directly observe how hypertrophic cardiomyopathy (HCM)-causing mutations and the HCM drug mavacamten affect the structure and function of...
- The federal Project Grant award of $507,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop an automated system that integrates micro-electromechanical sensors, automation, and machine vision to simultaneously measure electrophysiological properties and contractile forces in single human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). This innovative system is expected to significantly reduce measurement time...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $777,954 to the Icahn School of Medicine at Mount Sinai to conduct research on improving preconception cardiovascular health among adolescents. The key products and services to be delivered through this grant include: Constructing a school-based adolescent preconception cohort through data linkages to study the influence of school environments on cardiovascular risk...
- This Project Grant award of $511,987.00 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a comparative study on gene regulatory and structural mechanisms in lamin-related cardiomyopathy. The project aims to directly compare two prevailing hypotheses on the pathogenesis of lamin A/C-related dilated cardiomyopathy (LMNA-DCM) - the gene regulatory hypothesis and the structural hypothesis - to advance the mechanistic...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Albert Einstein College of Medicine provides $785,198 in funding to study the role of chaperone-mediated autophagy (CMA) in regulating cardiac fibroblast and myofibroblast function during heart repair following myocardial infarction. The research aims to investigate how CMA, a selective protein degradation process, modulates fibroblast phenotypic transitions and impacts...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $194,375 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, Santa Barbara (UCSB) to study the impact of cardiomyopathy-driven extracellular matrix (ECM) remodeling on myocardial viscoelasticity and its effects on cardiomyocyte phenotype. The 24-month project aims to: 1) Determine how cardiomyopathy alters myocardial viscoelasticity, and 2) Assess how matrix viscoelasticity regulates...